In this Quick Case, Endocrinologist A/Prof Samantha Hocking outlines evidence from the SURMOUNT-MAINTAIN study, demonstrating how tirzepatide dose reduction or elimination impacts the maintenance of weight loss, cardiometabolic benefits, and clinical decision-making in obesity management (5 mins).

The Peptide Craze – What You Need to Know

Managing Acute Heart Failure After Discharge: A Practical Guide for GPs

Oral Contraceptives on the PBS – A Practical Guide for GPs

The Impact of PFAS & Other Endocrine Disrupting Chemicals on Fertility

expert
Endocrinologist; Royal Prince Alfred Hospital; Clinical Academic at Charles Perkins Research Centre, University of Sydney; President, National Association of Clinical Obesity Services (NACOS)